| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 3.33B | — |
| Operating expense | — | — |
| Net income | 1.10B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, VX1.F returned +40.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +21.3% |
| 1 year | +40.8% |
| 5 years | +179.9% |
| 10 years | +460.8% |
| All-time high | €471.85 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in VX1.F would be worth today ›No. Vertex Pharmaceuticals Incorporated has not paid a dividend in the past 12 months.
Vertex Pharmaceuticals Incorporated is part of the Healthcare sector.
Vertex Pharmaceuticals Incorporated has a market cap of 119.60B EUR, based on the latest quote.
Vertex Pharmaceuticals Incorporated is expected to report earnings around Nov 2, 2026. That date is an estimate and has not been confirmed by the company.
